- Home
- FENC vs PROF Comparison
FENC vs PROF Comparison
Compare FENC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | PROF |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.3M | 230.4M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | PROF |
|---|---|---|
| Price | $7.57 | $8.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.00 | $12.00 |
| AVG Volume (30 Days) | 179.1K | ★ 288.0K |
| Earning Date | 03-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $38,790,000.00 | $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | $70.97 | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $4.68 | $3.76 |
| 52 Week High | $9.92 | $8.95 |
Technical Indicators
Market Signals| Indicator | FENC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 57.22 |
| Support Level | $7.35 | $7.45 |
| Resistance Level | $7.82 | $8.95 |
| Average True Range (ATR) | 0.39 | 0.58 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 31.06 | 61.13 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.